Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.32
  • Today's Change0.025 / 1.94%
  • Shares traded2.91k
  • 1 Year change-26.12%
  • Beta2.1171
Data delayed at least 15 minutes, as of Nov 21 2024 20:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy1
Outperform3
Hold10
Sell0
Strong Sell0

Share price forecast in USD

The 13 analysts offering 12 month price targets for Tilray Brands Inc have a median target of 2.00, with a high estimate of 4.00 and a low estimate of 1.75. The median estimate represents a 52.67% increase from the last price of 1.31.
High205.3%4.00
Med52.7%2.00
Low33.6%1.75

Earnings history & estimates in USD

On Oct 10, 2024, Tilray Brands Inc reported 1st quarter 2025 losses of -0.04 per share. This result was in line with the consensus of the 5 analysts following the company and exceeded last year's 1st quarter results by 60.00%.
The next earnings announcement is expected on Jan 07, 2025.
Average growth rate+6.31%
Tilray Brands Inc reported annual 2024 losses of -0.33 per share on Jul 29, 2024.
Average growth rate-1.53%
More ▼

Revenue history & estimates in USD

Tilray, Inc. had 1st quarter 2025 revenues of 200.04m. This missed the 219.30m consensus estimate of the 9 analysts following the company. This was 13.05% above the prior year's 1st quarter results.
Average growth rate+3.95%
Tilray, Inc. had revenues for the full year 2024 of 788.94m. This was 25.80% above the prior year's results.
Average growth rate+47.96%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.